SynthesisJournal of orthopaedic surgery and research2023
Duloxetine for fibromyalgia syndrome: a systematic review and meta-analysis.
Synthesis in Journal of orthopaedic surgery and research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 5 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Comparison of clinical efficacy of different acupuncture methods in the treatment of fibromyalgia: a network meta-analysis based on randomized controlled trials.Frontiers in neurology · 2026Pooled it
- Drug treatments for fibromyalgia: systematic review and network meta-analysis of randomised trials.BMJ medicine · 2026Pooled it
- Skeletal muscle relaxant for the treatment of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials.Regional anesthesia and pain medicine · 2025Pooled it
- Management of Juvenile Fibromyalgia: A Level I Evidence-Based Systematic Review.Medical sciences (Basel, Switzerland) · 2025Pooled it
- Duloxetine reduces opioid consumption and pain after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.Journal of orthopaedic surgery and research · 2024Pooled it
- Home-based postural exercise as an adjunct to duloxetine improves sleep quality, physical quality of life, and trunk mobility in fibromyalgia: a randomized controlled trial.Rheumatology international · 2026Trial
- Decoding pain in axial spondyloarthritis: Mechanisms, management, and future directions.Best practice & research. Clinical rheumatology · 2026Review
- Therapeutic potential of combining mirogabalin with antidepressants in relieving hypersensitivity: evidence from a mouse model of neuropathic pain.Pharmacological reports : PR · 2026Article
- Comparative effectiveness of antidepressants for depression using EHRs from two health systems.BMC psychiatry · 2026Article
- Inner ear signs and symptoms induced by antidepressants: a disproportionality analysis based on the FAERS database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Understanding Adherence to Duloxetine in Psychiatric Practice: A Cross-Sectional Evaluation of Clinicians' Experience.Brain sciences · 2026Article
- Review of fibromyalgia treatment guidelines: part 2 - pharmacological treatment.Advances in rheumatology (London, England) · 2026Review
- Central Sensitization and Nociplastic Pain: Shared Mechanisms in Fibromyalgia, Osteoarthritis, and Inflammatory Arthritis.Journal of pain research · 2026Review
- Descriptive analysis of prescription interception patterns: characterizing medication safety risks in an outpatient setting.Frontiers in pharmacology · 2026Article
- Delving into the Perception, Use, and Context of Duloxetine in Clinical Practice: An Analysis Based on the Experience of Healthcare Professionals.Brain sciences · 2025Article
- Review
- A Comprehensive Analysis of Fibromyalgia and the Role of the Endogenous Opioid System.Biomedicines · 2025Review
- Pharmacologic treatment of fibromyalgia: an update.Frontiers in pharmacology · 2025Review
- Pain Management in Fibromyalgia: Evaluating the Roles of Pregabalin, Duloxetine, and Milnacipran.Cureus · 2024Article
- How to Distinguish Non-Inflammatory from Inflammatory Pain in RA?Current rheumatology reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe optimal dose of duloxetine in the management of fibromyalgia remains still controversial. Therefore, a systematic review and meta-analysis to investigate efficacy and safety of duloxetine was conducted. The outcomes of interests were to assess changes in Fibromyalgia Impact Questionnaire (FIQ), Brief Pain Inventory (BPI), and Clinical Global Impression (CGI). The rate of of adverse events and those leading to therapy discontinuation were also investigated. MATERIAL AND
methodsThis study followed the 2020 PRISMA guidelines. The literature search started in December 2022 accessing PubMed, Google scholar, Embase, and Scopus databases. All the RCTs investigating the efficacy and safety of daily administration of duloxetine for fibromyalgia were accessed. Studies reporting quantitative data under the outcomes of interest, and including a minimum of 10 patients who completed a minimum of 4 weeks follow-up, were included. Studies on combined pharmacological and non-pharmacological managements for fibromyalgia were not considered.
resultsData from 3432 patients (11 RCTs) were included. The mean age of the patients was 46.4 ± 10.7 years old, and the mean BMI 25.3 ± 3.2 kg/m
conclusionsDuloxetine could help in improving symptoms of fibromyalgia. The dose of duloxetine should be customised according to individual patients. Irrespective of the doses, duloxetine was more effective than placebo in the management of fibromyalgia. The dose of duloxetine must be customised according to individual patients. Level of evidence I Meta-analysis of double-blind RCTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.